Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 6/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | GRK2 | P25098 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14973104 | 0.86 | CA9 (0.46) | CA12CA2CA9CPT2CPT1A | |
| SCHEMBL14973303 | 0.86 | CA12 (0.39) | TTKMAPK8CA12CA2CA9 | |
| SCHEMBL10060115 | 0.84 | CA12 (0.39) | TTKMAPK8CA12CA2CA9 | |
| SCHEMBL14973315 | 0.83 | CA9 (0.46) | CA12CA2CA9PDE4APDE4B | |
| SCHEMBL14973125 | 0.83 | CA2 (0.49) | CA12CA2CA9CA1 | |
| SCHEMBL14973212 | 0.81 | CA9 (0.37) | TTKKDRCA12CA2CA9 | |
| SCHEMBL14973179 | 0.79 | CA9 (0.46) | CA12CA2CA9CPT2CPT1A | |
| SCHEMBL14973289 | 0.78 | STAT3 (0.41) | — | |
| SCHEMBL14973301 | 0.77 | CA9 (0.46) | CA12CA2CA9CPT2CPT1A | |
| SCHEMBL14973059 | 0.77 | CA9 (0.45) | CA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604602-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | GRIN2C, GRIN2B, GRIN3A | TTK 1588/4885KDR 4760/4885MAPK8 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.